Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients - Archive ouverte HAL Access content directly
Journal Articles Clinical Cancer Research Year : 2011

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

Abstract

An ancillary phase II study was conducted to study interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and 5-fluorouracil.
Not file

Dates and versions

hal-01769933 , version 1 (18-04-2018)

Identifiers

Cite

Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, et al.. Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients. Clinical Cancer Research, 2011, 17 (19), pp.6329 - 6337. ⟨10.1158/1078-0432.CCR-11-1081⟩. ⟨hal-01769933⟩
100 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More